Drug treatment for multidrug-resistant Acinetobacter baumannii infections

被引：79

作者：

Bassetti, Matteo ^{[1
]}

Righi, Elda ^{[2
,3
]}

Esposito, Silvano ^{[4
]}

Petrosillo, Nicola ^{[5
]}

Nicolini, Laura ^{[2
,3
]}

机构：

[1] Univ San Martino, Azienda Osped, Clin Malattie Infett, I-16132 Genoa, Italy

[2] San Martino Hosp, Div Infect Dis, Genoa, Italy

[3] Univ Genoa, Sch Med, Genoa, Italy

[4] Univ Naples 2, Dept Infect Dis, Naples, Italy

[5] Natl Inst Infect Dis L Spallanzani, Rome, Italy

来源：

FUTURE MICROBIOLOGY | 2008年 / 3卷 / 06期

关键词：

Acinetobacter baumannii; antibiotic; colistin; imipenem; meropenem; resistance; rifampin; sulbactam; therapy; tigecycline;

D O I：

10.2217/17460913.3.6.649

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Acinetobacter boumannii has emerged in the last decades as a major cause of healthcare-associated Infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. boumannii Is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound Infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important hospital problem,

引用

页码：649 / 660

页数：12

共 137 条

[1] Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes [J].

Abbo, A. ;

Carmeli, Y. ;

Navon-Venezia, S. ;

Siegman-Igra, Y. ;

Schwaber, M. J. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (11) :793-800

[2] Multidrug-resistant Acinetobacter baumannii [J].

Abbo, A ;

Navon-Venezia, S ;

Orly, HM ;

Krichali, T ;

Siegman-Igra, Y ;

Carmeli, Y .

EMERGING INFECTIOUS DISEASES, 2005, 11 (01) :22-29

[3] Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii [J].

Afzal-Shah, M ;

Woodford, N ;

Livermore, DM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :583-588

[4]

Allen D.M., 2005, PRINCIPLES PRACTICE, Vsixth, P2632

[5]

AMYES SGB, 1996, ACINETOBACTER MICROB

[6]

[Anonymous], 2005, GLUCAGON HYPOKIT PAC

[7] The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].

Babinchak, T ;

Ellis-Grosse, E ;

Dartois, N ;

Rose, GM ;

Loh, E .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367

[8] Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections [J].

Baran, Guelseren ;

Erbay, Ayse ;

Bodur, Huerrem ;

Onguru, Pinar ;

Akinci, Esraguel ;

Balaban, Neriman ;

Cevik, Mustafa A. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (01) :16-21

[9] Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections [J].

Bassetti, M. ;

Repetto, E. ;

Righi, E. ;

Boni, S. ;

Diverio, M. ;

Molinari, M. P. ;

Mussap, M. ;

Artioli, S. ;

Ansaldi, F. ;

Durando, P. ;

Orengo, G. ;

Pallavicini, F. Bobbio ;

Viscoli, C. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :417-420

[10] EPIDEMIC BACTEREMIA DUE TO ACINETOBACTER-BAUMANNII IN 5 INTENSIVE-CARE UNITS [J].

BECKSAGUE, CM ;

JARVIS, WR ;

BROOK, JH ;

CULVER, DH ;

POTTS, A ;

GAY, E ;

SHOTTS, BW ;

HILL, B ;

ANDERSON, RL ;

WEINSTEIN, MP .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 132 (04) :723-733

← 1 2 3 4 5 6 7 8 9 10 →